Michael W. Kalb - Jan 1, 2024 Form 3 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Executive Vice President & CFO
Signature
/s/ Michael W. Kalb
Stock symbol
CPRX
Transactions as of
Jan 1, 2024
Transactions value $
$0
Form type
3
Date filed
1/3/2024, 05:18 PM
Previous filing
May 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CPRX Common Stock, par value $0.001 per share 0 Jan 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CPRX Options to purchase common stock Jan 1, 2024 Common Stock 257K $16.81 Direct F1
holding CPRX Restricted Stock Units Jan 1, 2024 Common Stock 35.7K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Derivative Securities vest in five annual tranches beginning on January 1, 2025.
F2 Shares of common stock will be delivered to the Reporting Person upon vesting.
F3 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.